0000899243-21-018665.txt : 20210507 0000899243-21-018665.hdr.sgml : 20210507 20210507161539 ACCESSION NUMBER: 0000899243-21-018665 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210505 FILED AS OF DATE: 20210507 DATE AS OF CHANGE: 20210507 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Noble James CENTRAL INDEX KEY: 0001388000 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35892 FILM NUMBER: 21902842 MAIL ADDRESS: STREET 1: 322 EAST MAIN STREET CITY: BRANFORD STATE: CT ZIP: 06405 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: GW PHARMACEUTICALS PLC CENTRAL INDEX KEY: 0001351288 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: SOVEREIGN HOUSE STREET 2: VISION PARK CITY: HISTON, CAMBRIDGE CB24 9BZ STATE: X0 ZIP: 00000 BUSINESS PHONE: 44 1223 266800 MAIL ADDRESS: STREET 1: SOVEREIGN HOUSE STREET 2: VISION PARK CITY: HISTON, CAMBRIDGE CB24 9BZ STATE: X0 ZIP: 00000 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-05-05 1 0001351288 GW PHARMACEUTICALS PLC GWPH 0001388000 Noble James SOVEREIGN HOUSE, VISION PARK, HISTON CAMBRIDGE X0 CB24 9BZ UNITED KINGDOM 1 0 0 0 Ordinary Shares 2021-05-05 4 D 0 27492 D 0 D Share Options 9.8117 2021-05-05 4 D 0 18636 D 2027-01-06 Ordinary Shares 18636 0 D Share Options 0.0017 2021-05-05 4 D 0 9168 D 2027-01-06 Ordinary Shares 9168 0 D Share Options 11.1742 2021-05-05 4 D 0 17676 D 2028-01-03 Ordinary Shares 17676 0 D Share Options 0.0017 2021-05-05 4 D 0 10740 D 2028-01-03 Ordinary Shares 10740 0 D Share Options 14.3342 2021-05-05 4 D 0 16548 D 2029-03-01 Ordinary Shares 16548 0 D Share Options 0.0017 2021-05-05 4 D 0 9432 D 2029-03-01 Ordinary Shares 9432 0 D Share Options 0.0017 2021-05-05 4 D 0 34416 D 2030-06-04 Ordinary Shares 34416 0 D Share Options 0.0017 2021-05-05 4 D 0 22464 D 2031-02-22 Ordinary Shares 22464 0 D On May 5, 2021, Jazz Pharmaceuticals Public Limited Company, a public limited company incorporated in the Republic of Ireland ("Jazz"), Jazz Pharmaceuticals UK Holdings Limited, a private limited company incorporated in England and Wales and an indirect wholly owned subsidiary of Jazz ("Bidco") and the DR Nominee (as defined in the Transaction Agreement) acquired all outstanding ordinary shares, par value British Pound Sterling 0.001 per share, of GW Pharmaceuticals plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement") (continued in footnote 2). At the effective time of the Scheme of Arrangement, Scheme Shareholders (as defined in the Scheme of Arrangement) became entitled to receive for each Scheme Share (as defined in the Scheme of Arrangement) held by them an amount equal to $16.66 2/3 in cash plus 0.010030 ordinary shares, nominal value $0.0001 per share, of Jazz. The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 15, 2021. Pursuant to the Transaction Agreement, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. /s/ James Noble 2021-05-07